The initial pharmacologic treatment for VT is:

The initial pharmacologic treatment for VT is:

• A. Antibiotics
• B. Diuretics
• C. Antiarrhythmic, e.g., amiodarone
• D. Anticoagulants

Answer: (C)

Managing ventricular tachycardia pharmacologically centers on using an antiarrhythmic to suppress the abnormal ventricular activity and restore a stable rhythm. The best initial drug for this is an antiarrhythmic such as amiodarone. Amiodarone is effective against a wide range of ventricular arrhythmias, works well in patients with structural heart disease, and has a favorable safety profile in acute settings, making it the preferred first-line choice. If the first-line agent isn’t available, lidocaine is an alternative, but amiodarone remains the standard due to its broad efficacy and lower proarrhythmic risk. Antibiotics, diuretics, and anticoagulants do not address the arrhythmia itself; they treat infections, fluid status, or thromboembolic risk, respectively, and would not terminate or adequately prevent VT.

Managing ventricular tachycardia pharmacologically centers on using an antiarrhythmic to suppress the abnormal ventricular activity and restore a stable rhythm. The best initial drug for this is an antiarrhythmic such as amiodarone. Amiodarone is effective against a wide range of ventricular arrhythmias, works well in patients with structural heart disease, and has a favorable safety profile in acute settings, making it the preferred first-line choice. If the first-line agent isn’t available, lidocaine is an alternative, but amiodarone remains the standard due to its broad efficacy and lower proarrhythmic risk.

Antibiotics, diuretics, and anticoagulants do not address the arrhythmia itself; they treat infections, fluid status, or thromboembolic risk, respectively, and would not terminate or adequately prevent VT.